Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 36Magnetic Resonance Spectroscopy 23Gemcitabine 19Specimen Handling 15Nivolumab 12Carboplatin 12Surveys and Questionnaires 11Paclitaxel 11Cetuximab 11Early Intervention, Educational 10Bevacizumab 10Standard of Care 9Cyclophosphamide 9Cisplatin 9Radiosurgery 8Methods 8Fluorouracil 8Docetaxel 8Blood Specimen Collection 8Psychiatric Rehabilitation 7Pemetrexed 7sargramostim 6aldesleukin 6Taxes 6Injections 6Fluorodeoxyglucose F18 6Educational Status 6Drug Therapy 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × BAY 1895344 × Gastrointestinal × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡